See more : The Kosei Securities Co., Ltd. (8617.T) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Svenska Handelsbanken AB (publ) (SHB-A.ST) Income Statement Analysis – Financial Results
- United Overseas Australia Limited (UOS.AX) Income Statement Analysis – Financial Results
- Benz Mining Corp. (BNZ.AX) Income Statement Analysis – Financial Results
- Chukyoiyakuhin Co.,Ltd. (4558.T) Income Statement Analysis – Financial Results
- Shanxi Coking Coal Energy Group Co.,Ltd. (000983.SZ) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences Surpasses USD $1.0 Million in Cumulative Direct Sales of Coffee with VINIA Inside
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 28, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that its VINIA® Superfood Coffee and Decaf...
BioHarvest Sciences to Host Second Quarter 2024 Corporate Update Call on August 29, 2024, at 2:30 p.m. Eastern Time
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 23, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will host a corporate...
BioHarvest Sciences sees record VINIA sales in May
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that sales of its flagship product VINIA increased to record levels in May 2024 due to strong subscription rates and the successful introduction of new products, such as VINIA Superfood Coffee. This surge was...
BioHarvest Sciences sees Q1 revenue surge above guidance on strong VINIA sales
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) saw its first quarter revenue surge almost 150% over the year-ago period driven by continued strong sales of its VINIA red grape superfood. Revenue for the quarter was US$5.34 million, up from US$2.2 million in...
BioHarvest Sciences Reports First Quarter 2024 Financial Results
Q1 2024 Revenue Increased 147% Year-over-Year to US$5.34 Million Exceeding Previous Guidance Management Expects Q2 2024 Revenue in the Range of US$5.7-6.0 Million Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 30, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB:...
BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 P.M. Eastern Time
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 1, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced that it will host a corporate...
BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results
FY 2023 Revenue Increased 2.3x to $12.7 Million USD The Company expects Q1 2024 Revenue to be in the range of $5.2 million to $5.3 million and is providing Q2 2024 Revenue Guidance of $5.7-$6.0 million Management pursuing Nasdaq listing...
BioHarvest Sciences unveils new state-of-the-art campus
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it has signed two agreements to create a new campus for its botanical synthesis contract development and manufacturing organization (CDMO) business unit in Yavne, Israel. The biotechnology firm, which is advancing its patented...
BioHarvest Sciences unveils new state-of-the-art campus
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it has signed two agreements to create a new campus for its botanical synthesis contract development and manufacturing organization (CDMO) business unit in Yavne, Israel. The biotechnology firm, which is advancing its patented...
BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity
80,000 Square Foot (7,500 Square Meter) Property includes 12 GMP Clean Rooms, Laboratory and Office space, and can accommodate expanded 50 Ton Manufacturing facility New Production Technologies Implemented at this Campus will serve to optimize the planned US-based 150-ton manufacturing...
Source: https://incomestatements.info
Category: Stock Reports